Symbols / RNAZ $8.60 -3.07% TransCode Therapeutics, Inc.

Healthcare • Biotechnology • United States • NCM
RNAZ Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
About

TransCode Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing drugs and diagnostics for treating and identifying cancer. The company's lead therapeutic candidate comprises TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in various cancers comprising breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. Its preclinical programs include TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1 and two indication agnostic programs; TTX-RIGA, an RNA- based agonist of the retinoic acid-inducible gene I targeting activation of innate immunity in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9-based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines that activate cytotoxic immune responses against tumor cells. TransCode Therapeutics, Inc. has strategic collaboration agreement with The University of Texas M. D. Anderson Cancer Center. The company was incorporated in 2016 and is based in Boston, Massachusetts.

Fundamentals
Scroll to Statements
Market Cap 7.88M Enterprise Value 131.61M Income -36.27M Sales — Book/sh 1.71 Cash/sh 19.43
Dividend Yield — Payout 0.00% Employees — IPO — P/E — Forward P/E -14.33
PEG — P/S — P/B 5.03 P/C — EV/EBITDA -6.88 EV/Sales —
Quick Ratio 5.37 Current Ratio 6.29 Debt/Eq — LT Debt/Eq — EPS (ttm) -52.59 EPS next Y -0.60
EPS Growth — Revenue Growth — Earnings 2025-04-15 ROA -14.14% ROE -46.26% ROIC —
Gross Margin 0.00% Oper. Margin 0.00% Profit Margin 0.00% Shs Outstand 916.97K Shs Float 832.42K Short Float 5.45%
Short Ratio 4.87 Short Interest — 52W High 22.04 52W Low 6.08 Beta 1.50 Avg Volume 209.71K
Volume 4.61K Target Price — Recom None Prev Close $8.87 Price $8.60 Change -3.07%
Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
—
Mean price target
2. Current target
$8.60
Latest analyst target
3. DCF / Fair value
$-265.67
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$8.60
Low
—
High
—
Mean
—

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2025-04-16 main HC Wainwright & Co. Buy → Buy $10
2025-03-13 reit HC Wainwright & Co. Buy → Buy $20
2025-02-07 reit HC Wainwright & Co. Buy → Buy $20
2025-02-06 reit HC Wainwright & Co. Buy → Buy $20
2024-12-18 main HC Wainwright & Co. Buy → Buy $20
2024-11-15 reit HC Wainwright & Co. Buy → Buy $3
2024-10-24 reit HC Wainwright & Co. Buy → Buy $3
2024-09-06 reit HC Wainwright & Co. Buy → Buy $3
2024-08-15 reit HC Wainwright & Co. Buy → Buy $3
2024-05-29 reit HC Wainwright & Co. Buy → Buy $3
2024-05-16 reit HC Wainwright & Co. Buy → Buy $3
2024-04-16 reit HC Wainwright & Co. Buy → Buy $3
2024-04-03 reit HC Wainwright & Co. Buy → Buy $3
News
RSS: Latest RNAZ news
Insider Transactions

No recent insider transactions.

Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.00
0.00
0.00
0.00
Operating Revenue
0.00
0.00
0.00
0.00
Operating Expense
17.92
+18.36%
15.14
-18.16%
18.50
+5.37%
17.55
Research And Development
13.42
+38.28%
9.71
-20.85%
12.26
+19.85%
10.23
Selling General And Administration
5.77
-3.08%
5.95
-16.78%
7.15
-14.84%
8.40
General And Administrative Expense
5.77
-3.08%
5.95
-16.78%
7.15
-14.84%
8.40
Other Gand A
5.77
-3.08%
5.95
-16.78%
7.15
-14.84%
8.40
Other Operating Expenses
-1.28
-143.84%
-0.52
+43.22%
-0.92
+14.57%
-1.08
Total Expenses
17.92
+18.36%
15.14
-18.16%
18.50
+5.37%
17.55
Operating Income
-17.92
-18.36%
-15.14
+18.16%
-18.50
-5.37%
-17.55
Total Operating Income As Reported
-27.98
-78.66%
-15.66
+19.35%
-19.42
-4.21%
-18.63
EBITDA
-34.31
-111.90%
-16.19
+9.90%
-17.97
-3.09%
-17.43
Normalized EBITDA
-17.72
-16.60%
-15.20
+15.44%
-17.97
-3.09%
-17.43
Reconciled Depreciation
0.11
-78.65%
0.53
+3.50%
0.52
+424.05%
0.10
EBIT
-34.43
-105.81%
-16.73
+9.53%
-18.49
-5.46%
-17.53
Total Unusual Items
-16.59
-1567.17%
-1.00
0.00
0.00
Total Unusual Items Excluding Goodwill
-16.59
-1567.17%
-1.00
0.00
0.00
Special Income Charges
-7.20
-1440732.00%
0.00
0.00
0.00
Restructuring And Mergern Acquisition
7.20
0.00
—
—
Net Income
-34.66
-106.87%
-16.75
+9.66%
-18.55
-5.59%
-17.56
Pretax Income
-34.44
-105.52%
-16.75
+9.66%
-18.55
-5.59%
-17.56
Net Non Operating Interest Income Expense
0.07
+111.65%
-0.62
-1131.05%
-0.05
-337.23%
-0.01
Interest Expense Non Operating
0.01
-75.33%
0.03
-52.03%
0.06
+74.76%
0.03
Net Interest Income
0.07
+111.65%
-0.62
-1131.05%
-0.05
-337.23%
-0.01
Interest Expense
0.01
-75.33%
0.03
-52.03%
0.06
+74.76%
0.03
Interest Income Non Operating
0.08
+11478.65%
0.00
-87.06%
0.01
-74.11%
0.02
Interest Income
0.08
+11478.65%
0.00
-87.06%
0.01
-74.11%
0.02
Other Income Expense
-16.59
-1567.17%
-1.00
—
—
Gain On Sale Of Security
-9.39
-842.94%
-1.00
—
—
Tax Provision
0.23
0.00
—
—
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
-3.48
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-34.66
-106.87%
-16.75
+9.66%
-18.55
-5.59%
-17.56
Net Income From Continuing Operation Net Minority Interest
-34.66
-106.87%
-16.75
+9.66%
-18.55
-5.59%
-17.56
Net Income From Continuing And Discontinued Operation
-34.66
-106.87%
-16.75
+9.66%
-18.55
-5.59%
-17.56
Net Income Continuous Operations
-34.66
-106.87%
-16.75
+9.66%
-18.55
-5.59%
-17.56
Normalized Income
-21.55
-36.76%
-15.76
+15.02%
-18.55
-5.59%
-17.56
Net Income Common Stockholders
-36.27
-116.09%
-16.79
+9.49%
-18.55
-5.59%
-17.56
Otherunder Preferred Stock Dividend
0.00
-100.00%
0.03
0.00
—
Diluted EPS
—
-1,336.63
+95.11%
-27,313.84
+97.36%
-1,033,233.41
Basic EPS
—
-1,336.63
+95.11%
-27,313.84
+97.36%
-1,033,233.41
Basic Average Shares
—
0.01
+1749.48%
0.00
+3894.12%
0.00
Diluted Average Shares
—
0.01
+1749.48%
0.00
+3894.12%
0.00
Diluted NI Availto Com Stockholders
-36.27
-116.09%
-16.79
+9.49%
-18.55
-5.59%
-17.56
Gain On Sale Of PPE
0.00
-100.00%
0.00
0.00
0.00
Preferred Stock Dividends
1.61
—
—
—
Total Other Finance Cost
—
0.60
—
—
Line Item Trend 2023-12-31
Total Assets
5.17
Current Assets
4.46
Cash Cash Equivalents And Short Term Investments
2.77
Cash And Cash Equivalents
2.77
Cash Financial
2.77
Receivables
0.00
Other Receivables
—
Prepaid Assets
0.54
Other Current Assets
1.15
Total Non Current Assets
0.71
Net PPE
0.60
Gross PPE
0.87
Accumulated Depreciation
-0.26
Machinery Furniture Equipment
0.38
Other Properties
0.48
Goodwill And Other Intangible Assets
—
Goodwill
—
Other Intangible Assets
—
Non Current Deferred Assets
—
Non Current Prepaid Assets
0.11
Total Liabilities Net Minority Interest
3.53
Current Liabilities
3.49
Payables And Accrued Expenses
3.05
Current Accrued Expenses
3.05
Current Debt And Capital Lease Obligation
0.41
Current Capital Lease Obligation
0.41
Current Deferred Liabilities
0.03
Current Deferred Revenue
0.03
Total Non Current Liabilities Net Minority Interest
0.04
Long Term Debt And Capital Lease Obligation
0.04
Long Term Capital Lease Obligation
0.04
Non Current Deferred Liabilities
—
Non Current Deferred Taxes Liabilities
—
Other Non Current Liabilities
—
Preferred Securities Outside Stock Equity
—
Stockholders Equity
1.64
Common Stock Equity
1.64
Capital Stock
0.00
Common Stock
0.00
Preferred Stock
0.00
Share Issued
0.00
Ordinary Shares Number
0.00
Treasury Shares Number
0.00
Additional Paid In Capital
48.06
Retained Earnings
-46.42
Total Equity Gross Minority Interest
1.64
Total Capitalization
1.64
Working Capital
0.96
Invested Capital
1.64
Total Debt
0.45
Capital Lease Obligations
0.45
Net Tangible Assets
1.64
Tangible Book Value
1.64
Derivative Product Liabilities
0.00
Duefrom Related Parties Current
—
Dueto Related Parties Current
—
Non Current Accrued Expenses
—
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-19.52
-46.34%
-13.34
+26.22%
-18.07
-14.67%
-15.76
Cash Flow From Continuing Operating Activities
-19.52
-46.34%
-13.34
+26.22%
-18.07
-14.67%
-15.76
Net Income From Continuing Operations
-34.66
-106.87%
-16.75
+9.66%
-18.55
-5.59%
-17.56
Depreciation Amortization Depletion
0.11
-78.65%
0.53
+3.50%
0.52
+424.05%
0.10
Depreciation
0.11
-78.65%
0.53
+3.50%
0.52
+424.05%
0.10
Depreciation And Amortization
0.11
-78.65%
0.53
+3.50%
0.52
+424.05%
0.10
Other Non Cash Items
5.25
—
—
—
Stock Based Compensation
0.49
-71.45%
1.70
+63.95%
1.04
+162.29%
0.40
Operating Gains Losses
9.28
+504.13%
1.54
—
—
Gain Loss On Investment Securities
9.28
+504.13%
1.54
—
—
Gain Loss On Sale Of PPE
—
—
—
0.00
Change In Working Capital
0.02
+104.43%
-0.35
+67.52%
-1.08
-182.69%
1.31
Change In Receivables
-0.95
0.00
-100.00%
0.36
+200.00%
-0.36
Change In Prepaid Assets
0.48
+17.68%
0.41
+11.76%
0.36
+351.25%
-0.14
Change In Payables And Accrued Expense
0.22
+163.11%
-0.34
+73.53%
-1.30
-170.29%
1.84
Change In Accrued Expense
—
—
—
0.00
Change In Payable
—
—
—
1.84
Change In Account Payable
—
—
—
1.84
Change In Other Working Capital
0.20
+12268.59%
-0.00
-106.09%
0.03
+188.63%
-0.03
Change In Other Current Assets
0.11
0.00
+100.00%
-0.11
0.00
Change In Other Current Liabilities
-0.04
+90.71%
-0.41
+2.85%
-0.42
0.00
Investing Cash Flow
-0.00
+79.61%
-0.02
+38.89%
-0.04
+64.72%
-0.10
Cash Flow From Continuing Investing Activities
-0.00
+79.61%
-0.02
+38.89%
-0.04
+64.72%
-0.10
Net PPE Purchase And Sale
-0.01
+69.39%
-0.02
+38.89%
-0.04
+64.72%
-0.10
Purchase Of PPE
-0.01
+69.39%
-0.02
+38.89%
-0.04
+64.72%
-0.10
Sale Of PPE
—
—
—
0.00
Capital Expenditure
-0.01
+69.39%
-0.02
+38.89%
-0.04
+64.72%
-0.10
Net Business Purchase And Sale
0.00
0.00
—
—
Financing Cash Flow
31.52
+92.20%
16.40
+3.09%
15.91
+265542.41%
0.01
Cash Flow From Continuing Financing Activities
31.52
+92.20%
16.40
+3.09%
15.91
+265542.41%
0.01
Net Issuance Payments Of Debt
—
—
—
—
Issuance Of Debt
—
—
—
—
Long Term Debt Issuance
—
—
—
—
Net Long Term Debt Issuance
—
—
—
—
Net Common Stock Issuance
8.85
-46.01%
16.40
+3.09%
15.91
0.00
Proceeds From Stock Option Exercised
—
—
0.00
-100.00%
0.01
Net Other Financing Charges
—
—
—
—
Changes In Cash
12.00
+294.37%
3.04
+238.29%
-2.20
+86.12%
-15.86
Beginning Cash Position
5.81
+109.97%
2.77
-44.30%
4.97
-76.14%
20.83
End Cash Position
17.81
+206.54%
5.81
+109.97%
2.77
-44.30%
4.97
Free Cash Flow
-19.52
-46.15%
-13.36
+26.24%
-18.11
-14.16%
-15.86
Interest Paid Supplemental Data
0.01
-60.91%
0.02
-49.40%
0.03
-11.46%
0.04
Income Tax Paid Supplemental Data
—
—
—
—
Change In Interest Payable
—
—
—
0.00
Common Stock Issuance
8.85
-46.01%
16.40
+3.09%
15.91
0.00
Issuance Of Capital Stock
31.52
+92.20%
16.40
+3.09%
15.91
0.00
Net Preferred Stock Issuance
22.67
0.00
—
—
Preferred Stock Issuance
22.67
0.00
—
—
Sale Of Business
0.00
0.00
—
—
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category